A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (NASH).
Phase of Trial: Phase III
Latest Information Update: 30 May 2016
At a glance
- Drugs Rimonabant (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Sanofi
- 03 Jul 2009 Additional location (United Kingdom) identified as reported by ClinicalTrials.gov.
- 17 Jun 2009 Actual patient number (165) added as reported by ClinicalTrials.gov.
- 17 Jun 2009 Actual initiation date changed from Dec 2007 to Jan 2008 as reported by ClinicalTrials.gov.